A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

What this study is about

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.

Who can join (things the study team will check)

✅ You may be able to join if…

• Have Body Mass Index (BMI) at screening of the following:
  • 30 kilogram per square meter (kg/m2) OR
  • 27 kg/m2 with at least one of the following weight-related health conditions at screening:
  • high blood pressure
  • dyslipidemia
  • obstructive sleep apnea, or
  • heart disease
• Have a stable body weight (<5% body weight change) for 90 days prior to screening.
• Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight

🚫 You may not be able to join if…

• Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
• Have type 1 diabetes or type 2 diabetes
• Have had within 90 days prior to screening:
  • heart attack
  • stroke
  • coronary artery revascularization
  • unstable angina, or
  • hospitalization due to congestive heart failure
• Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
• Have taken medications or alternative remedies intended for weight loss within 90 days of screening

Where this trial is running

• MFA Clinical Research, Tuscaloosa, Alabama, United States
• Headlands Research - Scottsdale, Scottsdale, Arizona, United States
• Neighborhood Healthcare Institute of Health, Escondido, California, United States
• Ark Clinical Research - Fountain Valley, Fountain Valley, California, United States
• Desert Oasis Healthcare Medical Group, Palm Springs, California, United States
• Peninsula Research Associates, Rolling Hills Estates, California, United States
• Care Access - Sacramento, Sacramento, California, United States
• Southern California Clinical Research, Santa Ana, California, United States
• University Clinical Investigators, Inc., Tustin, California, United States
• Chase Medical Research, LLC, Waterbury, Connecticut, United States
• JEM Research Institute, Atlantis, Florida, United States
• BioMed Research & Medical Center, Miami, Florida, United States

+ 157 more sites.

Who to contact

Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07321886.